Anti-CD19 CAR T cells for refractory myasthenia gravis

Aiden Haghikia(Otto-von-Guericke University Magdeburg), Tobias Hegelmaier(Otto-von-Guericke University Magdeburg), Denise Wolleschak(Otto-von-Guericke University Magdeburg), Martin Böttcher(Otto-von-Guericke University Magdeburg), Christiane Desel(Otto-von-Guericke University Magdeburg), Dominic Borie, Jeremias Motte(Ruhr University Bochum), Georg Schett(Friedrich-Alexander-Universität Erlangen-Nürnberg), Roland Schroers(Ruhr University Bochum), Ralf Gold(Ruhr University Bochum), Dimitrios Mougiakakos(Otto-von-Guericke University Magdeburg)
The Lancet Neurology
November 15, 2023
10.1016/s1474-4422(23)00375-7
Cited by 145Open Access
Full Text

Abstract

Related Papers

Myasthenia gravis
Alfred Jaretzki, Richard J. Barohn, Raina M. Ernstoff et al.|Neurology|2000|1.6k
Long-Lived Plasma Cells Are Contained within the CD19−CD38hiCD138+ Subset in Human Bone Marrow
Jessica L. Halliley, Christopher M. Tipton, Jane L. Liesveld et al.|Immunity|2015|539
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
Dimitrios Mougiakakos, Gerhard Krönke, Simon Völkl et al.|New England Journal of Medicine|2021|529
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
Jennifer N. Brudno, Norris Lam, Danielle Vanasse et al.|Nature Medicine|2020|312
Myasthenia gravis
U. A. Besinger, Klaus V. Toyka, Martina Hömberg et al.|Neurology|1983|274